This finding raises the question of whether NAFLD results in sarcopenia via activation of MSTN in skeletal muscle or whether sarcopenia is the primary abnormality related to MSTN and functions in an endocrine manner to activate fibrogenic hepatic stellate cells. This evidence concerns the gene MSTN and metabolic dysfunction-associated steatotic liver disease.